NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today ...
Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- ...
Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive ...
Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women's health, announced today that its core product APL-1702 (trade ...
Hosted on MSN
How Epinal’s Narcolyzer addresses a growing emergent need for non-invasive, rapid, handheld narcotics testing
Public institutions across the world are reassessing how they identify and respond to narcotic impairment. Courts, transportation agencies, probation departments, and treatment programs are ...
(Yicai) March 4 -- Shares of Asieris Pharmaceuticals soared by their daily trading limit after China granted the drugmaker marketing approval for Cevira, the world’s first non-surgical, non-invasive ...
Oncology Media Relations Oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com ...
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results